

Title	The presence of lymph node metastases and time to castration resistance predict the therapeutic effect of enzalutamide for castration-resistant prostate cancer
Author(s)	Oka, Toshiki; Hatano, Koji; Okuda, Yohei et al.
Citation	International Journal of Clinical Oncology. 2022, 28, p. 427-435
Version Type	AM
URL	https://hdl.handle.net/11094/90045
rights	
Note	

Osaka University Knowledge Archive : OUKA

<https://ir.library.osaka-u.ac.jp/>

Osaka University

Supplementary Table 1. Posterior sequential treatments after the end of enzalutamide treatment

Posterior sequential treatments, n (%)	Total (n=71)
Docetaxel	35 (49%)
Abiraterone acetate	14 (20%)
ADT only	12 (17%)
Dexamethasone	5 (7%)
Apalutamide	3 (4%)
Cabazitaxel	1 (1%)
Tegafur/uracil + dexamethasone	1 (1%)

ADT, androgen deprivation therapy